News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Algeta Release: New Data and Analyses From the Phase 3 ALSYMPCA Trial of Xofigo® (Radium Ra 223 Dichloride) Injection to be Presented at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013


9/12/2013 9:36:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Algeta ASA (OSE:ALGETA), announced today that further analyses of data subsets from the phase III ALSYMPCA study of Xofigo(®) (radium Ra 223 dichloride) injection will be presented at the 2013 European Cancer Congress (ECCO/ESMO/ESTRO), 28 September- 1 October, in Amsterdam, The Netherlands.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
Algeta AS
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES